Sézary T-cell-activating factor induces functional interleukin 2 receptors on T-cells derived from patients with Sézary syndrome

• Published in: Cancer research (Chicago, Ill.) Ill.), 1993-11, Vol.53 (22), p.5501-5506
• Main Authors: ABRAMS, J. T, GHOSH, S. K, DEFREITAS, E
• Format: Article
• Language: English
• Subjects: Biological and medical sciences; Electrophoresis, Polyacrylamide Gel; Hematologic and hematopoietic diseases; Humans; Interleukin-1 - isolation & purification; Interleukin-1 - pharmacology; Interleukin-2 - pharmacology; Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis; Medical sciences; Monocytes - drug effects; Monocytes - metabolism; Receptors, Interleukin-2 - drug effects; Receptors, Interleukin-2 - metabolism; Recombinant Proteins - pharmacology; Sezary Syndrome - metabolism; Skin Neoplasms - metabolism; T-Lymphocytes - chemistry; T-Lymphocytes - metabolism
• ISSN: 0008-5472; 1538-7445

Sézary syndrome is the leukemic form of cutaneous T-cell lymphoma characterized by circulating neoplastic CD4+ T-cells. Although peripheral blood mononuclear cells from patients with Sézary syndrome have been shown to respond poorly to mitogens, we found that mitogen-activated peripheral blood mononuclear cells from four of five patients with Sézary syndrome produce a 28 kDa protein termed Sézary T-cell activating factor (SAF). SAF renders nonproliferating "resting" T-cells from leukemic patients or healthy donors responsive to interleukin 2 in the absence of a costimulator. We demonstrate that SAF induces functional, high-affinity interleukin 2 receptors on T-cells from Sézary syndrome patients and provide evidence that SAF may be a novel cytokine.